Diagnosis and management of ADA2 deficient polyarteritis nodosa.
Adenosine Deaminase
/ deficiency
Genetic Predisposition to Disease
Hematopoietic Stem Cell Transplantation
Humans
Immunosuppressive Agents
/ adverse effects
Intercellular Signaling Peptides and Proteins
/ deficiency
Mutation
Phenotype
Plasma Exchange
Polyarteritis Nodosa
/ diagnosis
Predictive Value of Tests
Treatment Outcome
deficiency of ADA2
early-onset stroke
polyarteritis nodosa
vasculitis
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
pubmed:
7
4
2018
medline:
29
5
2019
entrez:
7
4
2018
Statut:
ppublish
Résumé
Deficiency of ADA2 (DADA2) is a recently described systemic inflammatory vasculopathy caused by mutations in the CERC1 gene that often, but not always, clinically resembles polyarteritis nodosa (PAN). The condition was originally characterized by livedoid rash, systemic inflammation, variable hypogammaglobulinemia, and early-onset stroke. The phenotypic spectrum has expanded to include patients with immunodeficiency syndromes and bone marrow dysfunction, which are not typical features of PAN. Exploration into the pathogenesis and treatment options of DADA2 has added to our understanding of this condition, but more studies are needed. The purpose of this article is to review the various clinical phenotypes of DADA2, and raise awareness among rheumatologists to consider DADA2 when evaluating patients presenting with PAN-like disease.
Identifiants
pubmed: 29624883
doi: 10.1111/1756-185X.13283
doi:
Substances chimiques
Immunosuppressive Agents
0
Intercellular Signaling Peptides and Proteins
0
ADA2 protein, human
EC 3.5.4.4
Adenosine Deaminase
EC 3.5.4.4
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
69-77Informations de copyright
© 2018 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.